diabigratan His name is, and seems to cause the disappearance of Sintrom known. This new drug is much more accurate and safe because of no need for periodic adjustments, leaving the patient more comfortable. The results of the study that has come to this conclusion was presented at the European Congress of Cardiology held last month in Barcelona and is published in the New England Journal of Medicine. The Sintrom is an anticoagulant to avoid episodes such as stroke and to prevent cardiovascular events . In Spain it takes about 800,000 people.
Patients who take it regularly must pass an analytical control every few weeks depending on the outcome of control taking into account the side effects it can cause bleeding such as frequent. The track is hard on the patient and a great burden on the healthcare system.
diabigratan The trials have been conducted in 44 countries, funded by Boehringer Laboratories, involved over 18,000 patients with atrial fibrillation. This disease affects a third of patients taking Sintrom. The study tested the efficacy of two doses, 110 and 150 mg, both twice daily. The highest is even more effective and the risk of bleeding is lower.
is currently only approved the drug agency in the U.S. (FDA) and Europe (EMEA). If everything is on track the new drug could be in pharmacies in about a year. Sergi López
Godia
Specialist Family and Community Medicine.
0 comments:
Post a Comment